-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
Registration
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
)
-
Cell Therapy Development
- Cell Therapy Development
Early analytical development and method validation strategies to ensure long-term clinical success E ... -
Cell Therapy Manufacturing
- Cell Therapy Manufacturing
The Future of Ex Vivo Manufacturing: Evolution or Extinction With advances in in vivo CAR engineerin ... -
Gene Therapy Development
- Gene Therapy Development
Which AAV analytical assays can be performed at low scale and with little to no purification early i ... -
Gene Therapy Manufacturing
- Gene Therapy Manufacturing
-
How can process control strategies and release/shelf‑life specifications be appropriately established when CMC timelines are compressed and early data come from limited clinical batches?
-
In what ways can Quality‑by‑Design (QbD) principles be applied to gene therapy CMC development to reduce long‑term lifecycle management burden?
-
Beyond the typical CQAs (genome titer, total particle number, infectivity, potency, aggregation, and particle composition), are there additional attributes that should be characterised for gene therapy products?
-
How should analytical methods for CQA testing be upgraded or expanded throughout product lifecycle management, given evolving platforms and limited industry standardisation?
-
What real‑world experiences demonstrate how automation improves consistency, reduces variability, and strengthens compliance in gene therapy manufacturing?
-
What examples exist of data modelling, AI, or digital‑twin technologies being applied to gene therapy manufacturing processes?
)
)
)
)
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
1-2-1 Meetings / Networking Break
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
1-2-1 Meetings / Networking Break
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
Morning Refreshments
-
Cell Therapy Manufacturing
- Cell Therapy Manufacturing
Platform flexibility to accelerate time to market Process flexibility to develop scalable, consisten ...
-
Gene Therapy Development
- Gene Therapy Development
Is frozen storage really unavoidable for viral vectors — or have we accepted it too easily as the de ...
)
)
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
Networking Lunch
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
)
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
1-2-1 Meetings / Networking Break
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
1-2-1 Meetings / Networking Break
-
Cell Therapy Manufacturing
- Gene Therapy Development
What are the advantages of assessing spatial biodistribution of analytes versus other approaches suc ...
-
Gene Therapy Development
- Gene Therapy Development
We developed an integrated workflow combining long-read sequencing and multiplex dPCR for comprehens ...
-
Gene Therapy Manufacturing
- Gene Therapy Manufacturing
MilliporeSigma's Viral Vector CDMO has developed a high-performing, scalable manufacturing platform ...
)
)
)
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
Afternoon Refreshments
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
1-2-1 Meetings / Networking Break
-
Cell Therapy Development
- Cell Therapy Development
What are the biggest barriers preventing broader implementation of automation in commercial cell the ... -
Gene Therapy Development
- Gene Therapy Development
What is the greatest challenge to increasing AAV potency in human tissues today—delivery to the targ ... -
Gene Therapy Manufacturing
- Gene Therapy Manufacturing
Scale up for In Vivo Extrahepatic Targeting As we move beyond liver-targeted therapies to extrahepat ...
)
)
-
- Cell Therapy Development
- Cell Therapy Manufacturing
- Gene Therapy Development
- Gene Therapy Manufacturing
Evening Drinks Reception